Ginkgo Bioworks

Historical price data

Ginkgo Bioworks' mission is to make biology easier to engineer by eliminating the manual lab work bottleneck through its autonomous lab platform. Founded by MIT scientists in 2009 and public since 2021, the company has established itself as a key infrastructure provider in synthetic biology, trusted by a diverse customer base. Its strategy is twofold: offering R&D-as-a-service through its Ginkgo Cloud Lab and licensing its technology stack for customers to build autonomous labs. Ginkgo's long-term ambition is to build a foundational data and execution platform for the entire bioeconomy.

An integrated autonomous lab platform combining robotics, AI software (e.g., Catalyst Agent), and a proprietary biological codebase to automate the design, build, and test cycles of biological engineering.

Ginkgo competes with large life science tool vendors (e.g., Thermo Fisher), specialized synthetic biology firms (e.g., Twist Bioscience), and the internal automation efforts of large biopharma/industrial companies. Its key differentiators are its full-stack integration, proprietary data asset (codebase), and flexible commercial models.